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Abstract
Simple, sensitive and specific predictors of mortality in the critically
ill remain elusive goals, and brain natriuretic peptide and venous
lactate are the subjects of recent studies. The role of vasopressin in
sepsis continues to be the focus of much research interest. Dose
ranging studies, potential adverse effects, and selective V1 agonists
are discussed below in recent trials. Finally the use of erythropoietin
in the critically ill continues to be studied but many continue to urge
caution for widespread use outside of clinical trials.
Predictors
The search for simple, sensitive and specific prognostic tools
in the critically ill population continues in the current literature.
Brain natriuretic peptide (BNP) has emerged during recent
years as a helpful tool in patients with cardiac failure, sepsis
and acute myocardial infarction (MI) [1]. Meyer et al.
investigated the prognostic impact of plasma N-terminal pro-
B-type natriuretic peptide (BNP) in an unselected cohort of
289 critically ill patients on admission to the intensive care
unit (ICU) [2].
ICU and hospital survivors had significantly lower BNP when
compared to non survivors (ICU BNP levels 3,394 versus
6,776 pg/mL, hospital BNP levels 2,656 versus 8,390 pg/mL,
p <0.001). There were no significant differences in BNP
values between those patients with a primary cardiac
diagnosis compared to those with a non cardiac diagnosis. A
logistic regression model showed that Simplified Acute
Physiology Score (SAPS) and BNP were independently
associated (p <0.008). The authors concluded that BNP may
facilitate triage in the critically ill.
Howell  et al. looked at the prognostic power of a single
presenting venous lactate and 28 day in-hospital mortality [3].
1,287 patients who presented to the accident and
emergency unit (A&E) with clinically suspected infection had
a single venous lactate measured. Lactate levels were
strongly associated with mortality even when stratified by
arterial blood pressure (p <0.0001). Normotensive patients
with a lactate >4 mmol/L had a 15% mortality, and overall
those patients with either a diagnosis of septic shock or a
lactate >4 had a mortality of 28%. In the absence of either
septic shock or a raised lactate the mortality was only 2.5%.
Lactate therefore has a significant prognostic value
independent of arterial pressure, and this study adds to other
work which has questioned the usefulness of blood pressure
in early warning scoring systems [4]. Raised lactate levels
allow early identification and therefore intervention in those
patients at high risk of death.
Pressors
Despite the myriad of trials investigating arginine vasopressin
(AVP) in the critically ill, its usefulness remains unclear.
Concerns have been raised over the possible side effects
including ischaemia of the mesentery, myocardium or
peripheries.
A poster presentation by Rehberg et al. compared the effects
of AVP and terlipressin (TP) on mesenteric blood flow and
mortality in established ovine sepsis [5]. In this septic shock
model, ewes were randomised to AVP, TP, or control, and all
groups were given norephinephrine (NADR) to maintain mean
arterial pressure (MAP) >70 mmHg. Mesenteric blood flow
was not affected by the administration of AVP or TP and
systemic haemodynamic parameters recovered better in the
AVP and TP groups. It is therefore reassuring that mesenteric
ischaemia was not a problem in this septic model.
Landry  et al. [6] have previously shown that NADR levels
increase whilst AVP levels decrease in septic shock, which
may explain why AVP replacement may improve haemo-
dynamic status. Barrett et al. have explored changes in
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vascular responsiveness to AVP and the selective V1 agonist,
F-180, in a long-term rodent model of sepsis [7]. Ex vivo
vascular reactivity is attenuated by NADR but increased with
AVP and to an even greater extent with F-180. The
implication is that the desired pressor response may be
specifically V1 mediated and therefore this should be where
future work in the critically ill patient should be focused.
A poster presentation by Traber et al. has also investigated a
selective V1 agonist FE 202158 [8]. The 20 mmHg drop in
MAP and 50% reduction in systemic vascular resistance in
their experimental model of septic shock was only partially
reversed with AVP but completely returned to pre-septic
levels with FE 202158. The septic control group accumu-
lated seven litres of fluid in 24 hours, as a probable
consequence of leaking capillaries. This fluid accumulation
was reduced by 50% in the AVP group and completely
prevented by the selective V1 agonist, FE 202158. However
in the latter group, the full prevention of this fluid and protein
leakage was reduced by 50%, by infusion of V2 agonist
desmopressin. The fluid accumulation findings suggest that
vasopressin, and in particular V1 receptors, play some direct
role in preventing vascular leak syndrome.
We eagerly await the published, peer-reviewed results of
current clinical trials on vasopressin in septic shock (VASST)
and terlipressin in septic shock (TESST), to determine if
these ‘bench’ findings translate to the ‘bedside’.
The most effective dose of AVP is also unclear and Luckner
et al. have performed a dose finding study comparing 0.03
with 0.067 IU/min of AVP infusions in addition to NADR
(mean dose 1.07 mcgs/kg/min) in 78 patients with advanced
vasodilatory shock [9]. Efficacy of treatment was determined
by increases in MAP and extent of NADR reduction. MAP
was higher (p <0.001), and NADR requirements were
reduced in the higher infusion group (p >0.001). In addition
lactate remained higher in the lower infusion group
suggesting that the higher dose was more effective in
reversing hypotension in sepsis.
Poietins
The increasing attempts to minimise the amount of allogeneic
transfusions due to both its potential risks and limitations as a
resource [10] has brought about an increasing enthusiasm for
other alternatives including the use of erythropoietin (EPO).
The EPO Critical Care Trial Group have extended research
previously involving mainly renal and oncology patients. Two
studies in critical care patients have previously observed a
reduction in requirement for blood transfusion [11,12], with a
suggestion that trauma patients may benefit further.
The EPO Critical Care Trial Group carried out a prospective,
randomised, double blinded, placebo-controlled, multicentre
study which recruited 1,460 medical and surgical patients
between 48-96 hours after admission to ICU. Patients at high
risk of thrombosis were excluded [13]. The treatment group
received EPO 40,000 U s/c once a week for three weeks, if
Hb <12 g/dl.
The primary endpoint result showed no reduction in
transfusion (46% versus 48% p = 0.34), a moderate increase
in Hb at day 29 in the EPO group and a lower overall 29 day
mortality for EPO (8.5% versus 11.4% p = 0.02). This
reduction in mortality extended to 140 days in the subgroup
of trauma patients (6.0% versus 9.26% p = 0.04, adjusted
hazard ratio 0.4, 95% CI 0.23-0.69).
The EPO group had an increased number of thrombotic
events (16.5% versus 11.5% p = 0.008) despite receiving
only one to three doses, although the authors suggested that
post hoc analysis showed that this was not significant in
patients who had received prophylactic heparin.
The authors observed that the surprise lack of reduction in
transfusions may be the result of the general adoption of a
restrictive strategy following the Transfusion Requirements in
Critical Care (TRICC) study [14]. The unexpected mortality
benefit despite no drop in transfusion may be accounted for
by protective nonhaemopoietic effects of EPO.
A recent meta analysis by Zarychanski et al. showed that EPO
had no statistical impact on overall mortality, length of stay or
duration of mechanical ventilation, but did show that EPO
reduced the chance of receiving a blood transfusion. [15] The
lack of effect on mortality may reflect the heterogeneity of
clinical trials examined in this meta-analysis, with no controls
for differing EPO doses, length of treatment and so on.
It remains important to pursue ways of minimising trans-
fusions and the EPO agonists may indeed play a crucial part.
The potential of other EPO agonists was recently highlighted
in  The Lancet with the use of Mircera (Maintenance of
Haemoglobin Excels in Intravenous Administration of CERA
[MAXIMA] study) [16].
Although there may be a real reduction in mortality in trauma
patients with EPO, this requires further investigation with
appropriately powered trauma specific studies. We must
continue therefore to exercise caution with EPO use in the
critically ill, a message reinforced by other editorialists [17].
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